TRPV2 channel negatively controls glioma cell proliferation and resistance to Fas-induced apoptosis in ERK-dependent manner

Massimo Nabissi1, Maria Beatrice Morelli1,2, Consuelo Amantini1, Valerio Farfariello1,2, Lucia Ricci-Vitiani3, Sara Caprodossi1, Antonella Arcella4, Matteo Santoni2, Felice Giangaspero2, Ruggero De Maria3 and Giorgio Santoni1,*

1Department of Experimental Medicine and Public Health, University of Camerino, 62032 Camerino (Macerata), Italy, 2Department of Experimental Medicine, University “La Sapienza”, 00100 Rome, Italy and 3Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Mediterraneo Neuromed, 86077 Pozzilli (Isernia), Italy

*To whom correspondence should be addressed. Tel: 39 0737 403312/403319; Fax: 39 0737 403325;

Email: giorgio.santoni@unicam.it

The aim of this study was to investigate the expression and function of the transient receptor potential vanilloid 2 (TRPV2) in human glioma cells. By Real-Time–PCR and western blot analysis, we found that TRPV2 messenger RNA (mRNA) and protein were expressed in benign astrocyte tissues, and its expression progressively declined in high-grade glioma tissues as histological grade increased (n = 49 cases), and in U87MG cells and in MZC, FCL and FSL primary glioma cells. To investigate the function of TRPV2 in glioma, small RNA interfering was used to silence TRPV2 expression in U87MG cells. As evaluated by RT-Profiler PCR array, siTRPV2-U87MG transfected cells displayed a marked downregulation of Fas and proapoptase-8 mRNA expression, associated with upregulation of cyclin E1, cyclin-dependent kinase 2, E2F1 transcript factor, V-raf-1 murine leukemia viral oncogene homolog 1 and Bel-2-associated X protein (Bel-X) mRNA expression. TRPV2 silencing increased U87MG cell proliferation as shown by the increased percentage of cells incorporating 5-bromo-2-deoxyuridine expressing βgal and rescued glioma cells to Fas-induced apoptosis. These events were dependent on extracellular signal-regulated kinase (ERK) activation: indeed inhibition of ERK activation in siTRPV2-U87MG transfected cells by treatment with PD98059, a specific mitogen-activated protein kinase/extracellular signal-regulated kinase inhibitor, reduced Bel-X, protein levels, promoted Fas expression, and restored Akt/protein kinase B pathway activation leading to reduced U87MG cell survival and proliferation, and increased sensitivity to Fas-induced apoptosis. In addition, transfection of TRPV2 in MZC glioma cells, by inducing Fas overexpression, resulted in a reduced viability and an increased spontaneous and Fas-induced apoptosis. Overall, our findings indicate that TRPV2 negatively controls glioma cell survival and proliferation, as well as resistance to Fas-induced apoptotic cell death in an ERK-dependent manner.

Introduction

Diffusely infiltrating gliomas are the most common primary brain tumors. They are characterized by diffuse infiltration of adjacent brain structure and tendency for progression to anaplasia over the time. Glioblastoma multiforme (GBM) represents the end of the spectrum of malignancy of these neoplasms (1,2). Despite advances in medical and surgical therapies, the outcome for patients diagnosed with GBM remains dismal. Two major features of GBM aggressiveness are high proliferation rate and resistance to chemotherapeutic drug-induced apoptosis (3).

Apoptosis can be triggered by several cell surface receptors belonging to the family of death receptors such as tumor necrosis factor receptor superfamily, member 6 (Fas) and tumor necrosis factor receptors (4). Fas has the ability to interact with the Fas-associated death domain that recruits procaspase-8 to form the death-inducing signalling complex (4,5); in addition, Fas signalling and apoptotic cell death can also be induced in a caspase-8-independent manner (6–8).

The Raf/mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) pathway regulates cell proliferation, differentiation, and apoptotic cell death in high-grade gliomas (9). Activation of Raf triggers the downstream serine-threonine kinase V-raf-1 murine leukemia viral oncogene homolog 1 (Raf-1), which in turn activates MEK that phosphorylates and activates p42/p44 mitogen-activated protein kinase (ERK) (10). ERK1/2 activation then leads to phosphorylation of a variety of substrates and transcription factors that ultimately contribute to induction of gene expression and proliferation (11).

ERK1/2 activation has been also implicated in cellular protection from various apoptotic signals (11,12). Thus, Fas-mediated signalling in Jurkat T cells is abrogated by ERK activation (13), and ERK activity inhibits caspase-8 cleavage but not death-inducing signalling complex assembly (6).

Members of transient receptor potential vanilloid (TRPVs) channel family control cellular homeostasis by regulating calcium influx, cell proliferation, differentiation, and apoptosis. Moreover, in the last years, an additional pathophysiological role for TRPV channel family in malignant growth and progression has been demonstrated (14,15). In this regard, we have recently reported a marked loss of transient receptor potential vanilloid type 1 (TRPV1) channel in high-grade gliomas, and TRPV1 involvement in the triggering of p38 MAP kinase (p38) mitogen-activated protein kinase (MAPK)-dependent GBM cell apoptosis in response to its specific agonist, capsaicin (16).

Transient receptor potential vanilloid type 2 (TRPV2), also called vanilloid receptor like-1 (VR1L-1), is another member of TRPV cation channel family. Like TRPV1, this receptor is predicted to contain six transmembrane domains, a putative pore-loop region, a cytoplasmic amino terminus with three ankyrin-repeat domains, and a cytoplasmic carboxy terminus (17). TRPV2 shows high Ca2+ permeability; functional studies have revealed that TRPV2 responds to noxious heat with an activation threshold of >52°C (17), as well as to changes in osmolarity and membrane stretch (18); in addition, TRPV2 is triggered by agonists such as 2-aminoethoxydiphenyl borate (19), as well as cannabidiol and Δ(9)-tetrahydrocannabinol (20).

Although the gene encoding TRPV2 is highly expressed in the central nervous system (17), TRPV2 transcripts are also found in non-neuronal tissues (17,21–23), suggesting that TRPV2 subserves a relatively broad repertoire of physiological functions.

In non-neuronal cells, TRPV2 channel activity can be regulated by growth factor signalling (24). In this regard, the mouse ortholog of TRPV2 (mTRPV2) is activated by growth factors such as insulin growth factor-1, platelet-derived growth factor, and the neurotrophic factor, 52C (17), as well as to changes in osmolarity and membrane stretch (18); in addition, TRPV2 is triggered by agonists such as 2-aminoethoxydiphenyl borate (19), as well as cannabidiol and Δ(9)-tetrahydrocannabinol (20).
head activator, suggesting a role for TRPV2 in cell growth and the alternative appellation of growth receptor channel. Growth factors induce translocation of TRPV2 channel from the intracellular compartments to the plasma membrane through phosphorylation of the P3 kinase (PI3 kinase)-dependent and -independent pathways (24,25). In addition, transfection of mTRPV2 in human embryonic kidney 293 cells induces intracellular calcium overload and a PI3-kinase-dependent cell death (25); moreover, myocytes from TRPV2 transgenic mice undergo extensive apoptosis (26). Finally, a role for TRPV2 in migration of prostate cancer cells induced by lysophospholipid stimulation has been reported (27).

Data concerning the function of endogenous TRPV2 have not been provided in a fair fashion. Therefore, we investigated the expression of TRPV2 in glioma cells and tissues, both at messenger RNA (mRNA) and protein levels. Moreover, by employing small RNA interference to knockdown TRPV2 gene expression in U87MG glioma cells, we demonstrated a role for this channel receptor in the control of glioma cell proliferation and resistance to Fas-induced apoptosis, by regulating ERK1/2 activation.

Materials and methods

Cells and tissues

The U87MG glioma cell line (American Type Culture Collection, LGC Promochem, Teddington, UK) and the primary glioblastoma cell lines MZC, FSL, and FCL, derived from bioptic samples surgically removed from patients who underwent surgery at the National Hospital (Londres, UK), were used as glioma cell lines. These cells were cultured in DMEM containing 10% FCS, 100 IU/ml penicillin, 100 μg streptomycin, non-essential amino acids and 1 mM sodium pyruvate. All cell lines were maintained at 37°C, 5% CO2 and 95% of humidity. Paraffin-embedded glioma tissues (n = 49) and benign astrocyte tissues (n = 7) were prepared from biopsy samples surgically removed from patients who gave informed consent to the study. Brain tumors of astrocytic origin were grouped according to malignancy grade II (n = 25), III (n = 13), IV (n = 11); (World Health Organization classification) (1). Primary glioma cell lines and glioma tissues are available at the Human Glioma Bank INM Neuromed (Pozzilli, Isernia, Italy).

Reagents and antibodies

Etosipide (VP-16), c1,3-bis(2-chloroethyl)-1-nitrosurea (BCNU, carmustine), 5-bromo-2-deoxyuridine (BrDU) and the MEK inhibitor PD98059 were purchased from Sigma-Aldrich (St Louis, MO), and Tocris Bioscience (Bristol, UK), respectively. The following mouse monoclonal antibodies (mAbs) were used: anti-β-actin (1:1000; Santa Cruz Biotechnology, Santa Cruz, CA), anti-Fas (1:1000; Sigma-Aldrich), antiphospho ERK (1:1000; Cell Signaling Technology, Danvers, MA), anti-Bcl-XL (1:200; Santa Cruz Biotechnology), anti-aspase-8 (1:4000; BD Biosciences, San Jose, CA), anti-phospho-p38 MAPK (1:1000; Cell Signaling Technology), anti-phospho-p44/42 MAPK (1:1000; Cell Signaling Technology), anti-Bax (1:200; Santa Cruz Biotechnology), anti-Fas (clone CH-11) (MBL Corporation, Woburn, MA). The following polyclonal antibodies (Abs) were used: goat-anti-TRPV2 (1:200; Santa Cruz Biotechnology), rabbit-anti-ERK (1:1000; Santa Cruz Biotechnology), rabbit-anti-glial fibrillary acidic protein (GFAP; 1:100; Cell Signaling Technology), rabbit-anti-Akt (1:1000; Signalway Antibody, Pearland, TX), rabbit anti-phospho Akt (1:1000; Cell Signaling Technology), rabbit anti-p38 MAPK (1:1000; Cell Signaling Technology), phospho-p38 MAPK (1:1000; Cell Signaling Technology), phospho-p44/42 MAPK (1:1000; Cell Signaling Technology), and phospho-ERK (1:1000; Cell Signaling Technology), horseradish peroxidase-conjugated donkey antigoat IgG (1:2000; Santa Cruz Biotechnology), horseradish peroxidase-conjugated goat anti-mouse IgG (1:4000; Bio-Rad), horseradish peroxidase-conjugated goat antimouse IgA (1:1000, GE Healthcare Europe GmbH, Milano, Italy), horseradish peroxidase-conjugated donkey antirabbit IgG (1:5000; GE Healthcare) were used as secondary Abs.

Total RNA extraction and complementary DNA synthesis

Total RNA from cell samples and paraffin-embedded sections (5–7 μm thick), was extracted accordingly to the manufacturer’s instructions, with the RNeasy Mini Kit (Qiagen GmbH, Hilden, Germany) and the Optimum FFPE RNA isolation kit (Applied Biosystems, Foster City, CA), respectively. Total RNA (100 ng for each sample) was treated with 1 U/ml of DNase I (Qiagen GmbH) and reverse transcribed into complementary DNA (cDNA), in a final volume of 25 μl, using the High-Capacity cDNA Archive Kit (Applied Biosystems). One microtiter of the resulting cDNA products was used as template for duplex real-time PCR (dRT–PCR) quantification.

Probes and primers

DxRT–PCR was performed using human TRPV2 and β-actin probes–primers designed with Primer Premier 5 (Bio-Rad, Hercules, CA) purchased from Sigma-Aldrich. Primers and probes sequences were: β-actin: forward: 5’-GAC ATG CAC AAA GAC GTG TAC G-3’; reverse: 5’-GCC AGG GCA GTG ATC TCC TCC T-3’; probe (Fam): 5’-TGC TGT CTG GCG GCACCA CCA TGG-3’; TRPV2: forward: 5’-GCC AGA GAG GCC AGA AAG AGC G-3’; reverse: 5’-CAC AGA AGC GAC GTG ATG CAC C-3’; probe (Texas Red): 5’-ACC CGG AGA GCC CCA TAG CAC CA-3’.

DxRT–PCR analysis

DxRT–PCR was performed using the iQ5 Multicolor Real-time PCR Detection System (Bio-Rad). The reaction mixture contained the AB RQ Mix for RT–PCR (AB Analytica, Padova, Italy), primer sets (200 nM for β-actin; 100 nM for TRPV2) and probe sets (100 nM for β-actin and 200 nM for TRPV2) in a total volume of 25 μl. Each amplification consisted of heat activation for 3 min at 95°C followed by 40 cycles at 95°C for 1 min and 60°C for 1 min. All samples were assayed in triplicate in the same plate and in three different experiments. Measurement of β-actin levels was used to normalize mRNA contents and TRPV2 levels, calculated by the 2−ΔΔCt method, were expressed as relative fold compared with benign astrocyte tissues used as control.

Cell transfections

siGENOME SMARTpoolts for TRPV2 (siTRPV2) consisting of four RNA duplex targeting TRPV2 gene, and a siCONTROL non-targeting small interfering RNA (siGLO) with at least four mismatches to any human gene used as negative control, were purchased from Dharmacon (Lafayette, CO). The expression vectors pHCMV-FSR was purchased from Genlantis (San Diego, CA). The plasmid encoding human TRPV2 was constructed by introducing in frame TRPV2 cDNA in BglII/HindIII PCMV-FSR cloning sites. For transfection experiments, U87MG and MZC glioma cells were plated at the density of 2 × 104/cm2 and after an overnight incubation, 50 nM of siTRPV2 or siGLO and 1 μg/ml of PCMV-TRPV2 or PCMV (empty vector) were added to the wells, following MAFECTENNE PRO transfection protocol. Cells were harvested up to day 3 post-transfection for analysis. The efficiency of transfection were evaluated by dxRT–PCR and western blot analysis.

Cancer pathway finder profile analysis

The Human Cancer Pathway Finder™ PCR Array and related reagents were purchased from SABiosciences (Frederick, MD). Total RNA from siGLO- and siTRPV2-U87MG transfected cells at day 3 post-transfection was extracted and 2 μg of total RNA from each sample were subjected to reverse transcription in a total volume of 20 μl using the ReactionReady™ first strand cDNA (SABiosciences). cDNAs were analyzed by quantitative RT–PCR performed using a Q5 Multicolor Real-time PCR Detection system, the SuperArray’s RT2™ Real-time SYBR Green PCR Master Mix and the Human Pathways CancerFinder™ (SABioscience) according to manufacturer’s instructions. Measurement of the expression of two housekeeping genes (β-actin, glyceraldehydes-3-phosphate dehydrogenase) on the samples was used to normalize mRNA content, and the gene expression levels of siTRPV2-transfected cells were expressed as relative fold respect to siGLO-U87MG transfected cells. Data acquisition was performed using the web-based integrated PCR Array Data Analysis Template provided by SABiosciences.

Western blot

Glioma cells and tissues were lysed in lysis buffer (1 M Tris pH 7.4, 1 M NaCl, 10 mM ethylene glycol-bis(aminohexylether)-1-tetraacetic acid, 100 mM NaF, 100 mM Na2VO4, 100 mM phenylmethylsulfonyl fluoride, 2 mM deoxycholate, 100 mM ethylenediaminetetraacetic acid, 10% Triton X-100, 10% glycerol, 10% sodium dodecyl sulfate, 0.1 M Na3P04) containing protease inhibitor cocktail (Sigma-Aldrich) by using a Mixer Mill MM300 (Qiagen GmbH). Lysates were separated on sodium dodecyl sulfate polyacrylamide gel (7–12%) and transferred onto Hybond-C extra membranes (GE Healthcare). Non-specific binding sites were blocked with 5% low-fat dry milk in phosphate-buffered saline (PBS) Tween 20 for 1 h at room temperature. Blots were incubated for 1 h with the primary Abs in PBS–Tween 20 supplemented with 3% low-fat dry milk, washed three times with PBS–Tween 20 buffer, and incubated with the appropriate secondary Abs. Immunostaining was revealed by enhanced ECL Western Blotting analysis system (GE Healthcare). Densitometric analysis was performed by ChemiDoc by using the Quantity One software (Bio-Rad).

3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay

Glioma cells were cultured with different doses of VP-16, BCNU or anti-Fas mAb, alone or in combination, and the percentage of cytotoxicity was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
M. Nabissi et al.

(MTT) assay. Briefly, $1 \times 10^4$ cells per cm$^2$ were plated in a 96-well plate and then cultured, up to 3 days with the appropriated drugs, in the presence or not of PD98059 (50 $\mu$M). Four replicates were used for each treatment. At the indicated time, 0.8 mg/ml of MTT was added to the media and incubated for 3 h. Then the supernatants were discarded and colored formazan crystals, dissolved with 100 $\mu$l of dimethyl sulfoxide, were read by an enzyme-linked immunosorbent assay reader (BioTek Instruments, Winooski, VT). Sample data are represented as the average of at least three separate experiments.

**Immunofluorescence and fluorescence activated cell sorting analysis**

BrdU incorporation in U87MG-transfected cells was determined by seeding 3 $\times$ 10$^4$/cm$^2$ cells into six-well plates and assayed at 72 h after transfection. One day before harvesting, cells were labeled by adding 20 $\mu$l BrdU. After trypsinization and washing in PBS supplemented with 0.5% bovine serum albumin and 2 mM ethylenediaminetetraacetic acid, cells were fixed for 30 min in PBS solution containing 30% methanol and 0.4% parafomaldehyde, permealized with a PBS solution containing 1% paraformaldehyde and 0.01% Tween-20, and then incubated for 15 min in DNAse buffer containing 500 KU/ml of DNAse (Sigma-Aldrich). Thereafter, cells were stained with a 1:10 dilution of anti-BrdU FITC-conjugated Ab, incubated for 1 h at room temperature and washed in PBS solution containing 0.5% bovine serum albumin and 2 mM ethylenediaminetetraacetic acid. In some experiments, transfected U87MG cells were pulsed for 24 h with BrdU and subsequently stained with FITC-conjugated anti-BrdU mAb, anti-GFAP or anti-ß-tubulin, and their respective phycoerythrin-conjugated goat antirabbit or goat antimouse secondary polyclonal Ab.

Samples were analyzed by a FACScan cytometer using the CellQuest software (BD Pharmingen, San Diego, CA), and fluorescence intensity was expressed in arbitrary units on logarithmic scale.

Mitochondrial transmembrane potential ($\Delta$Psi$m$), in U87MG-transfected cells, was evaluated by 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB) assay. Briefly, $1 \times 10^4$/cm$^2$ cells were treated with the appropriated drugs, at different concentrations, and then incubated for 10 min at room temperature with $300 \mu$l of 10 $\mu$M MitoTracker Deep Red FM. The fluorescence intensity was expressed as fold change with respect to control. Statistical analysis was performed comparing tissues and cell lines with control, using non-parametric analysis of variance (Kruskal-Wallis test) and post-tests (Bonferroni and Dunn multiple comparisons).

**Apoptosis assays**

Phosphatidylserine exposure on U87MG and MZC glioma cells was detected by Annexin-V staining and cytofluorimetric analysis. Briefly, $1 \times 10^4$/cm$^2$ cells were treated with different doses of the appropriated drugs for 72 h in 96-well plates. After treatment, cells were stained with 5 $\mu$l of Annexin-V-FITC for 10 min at room temperature and washed once with binding buffer (10 mM HEPES/NaOH, pH 7.4, 140 mM NaCl, 2.5 mM CaCl$_2$).

**Statistical analysis**

The statistical significance was determined by Student’s t-test and by Bonferroni post-test (one-way ANOVA; $P < 0.01$).

**Results**

**Expression of TRPV2 mRNA and protein on glioma tissues and cell lines**

We determined TRPV2 mRNA expression in glioma tissues with different grades, as well as in U87MG and MZC, FCL, and FSL primary glioma cells by dxRT–PCR; we found that TRPV2 mRNA levels were expressed in benign astrocyte control tissues and its expression progressively declined in low- (grade II) versus high-grade gliomas (grades III and IV); furthermore, TRPV2 mRNA expression was markedly reduced in U87MG cells, and strongly downregulated in MZC, FCL, and FSL primary glioma cells as compared with controls (Figure 1A). Consistent with dxRT–PCR data, a progressive reduction of TRPV2 protein expression was evidenced by western blot analysis in glioma tissues as pathological grade increased, with a complete loss in grade IV glioblastomas (Figure 1B), as well as in U87MG and MZC glioma cells (Figure 1C). No reactivity was observed with normal goat serum used as negative control (data not shown).

In conclusion, the loss of TRPV2 expression in high-grade glioblastoma cells and tissues suggests a negative role for TRPV2 in tumor progression.

**TRPV2 silencing affects gene expression in U87MG cells**

In order to study the functional role of TRPV2 in glioma cells, we silenced TRPV2 gene in U87MG cells by small RNA interference. No changes in cell viability, morphology, and adhesive properties were observed in transfected versus untransfected U87MG cells (data not shown). As evaluated by dxRT–PCR, a progressive decrease of TRPV2 mRNA levels from day 1 up to day 4 post-transfection was observed in siTRPV2-transfected cells, with a marked loss detected already at day 2 (Figure 2A); similarly, western blot analysis revealed a parallel decrease of TRPV2 protein at day 3 (Figure 2B). No major differences in TRPV2 mRNA expression were observed in siGLO-transfected cells.

Thereafter, we investigated the role of TRPV2 in glioma cells, by exploring the expression of 84 genes representative of six biological pathways involved in transformation and tumorigenesis, in siTRPV2- and siGLO-U87MG transfected cells by performing an RT-Profiler.
PCR array using a customized Cancer Pathway Finder PCR array. TRPV2 silencing significantly modulated the expression of genes controlling cell cycle, proliferation and apoptosis being five genes upregulated and two genes downregulated. Among them, expression of cyclin E1, cyclin-dependent kinase 2, E2F1 transcriptor factor 1, Raf-1 and the anti-apoptotic Bcl-XL genes was increased, whereas reduced expression of death receptor apoptosis-related genes, such as Fas and procaspase-8, was observed (Figure 2C).

Overall, our data indicate that silencing of TRPV2 in U87MG cells promotes a genetic program favoring cell proliferation and survival, thus suggesting that this receptor negatively controls glioma growth and progression.

**ERK phosphorylation is increased in TRPV2-silenced U87MG cells**

Our finding that Raf-1 mRNA is upregulated in siTRPV2-U87MG cells together with the major role described for ERK1/2 and p38MAP kinases in the control of glioma cell proliferation and apoptosis (9,16) prompted us to evaluate the ERK1/2 phosphorylation status in siTRPV2-U87MG transfected cells. We found enhanced ERK phosphorylation in siTRPV2-U87MG transfected cells, which was completely inhibited by the specific pharmacological MEK inhibitor PD98059 (Figure 3A). As previously described, ERK was phosphorylated at basal level in U87MG cells (28); no statistically significant changes in ERK protein and phosphorylation levels were found in PD98059-treated compared with siGLO-U87MG cells (data not shown). Moreover, PD98059, at the dose that completely inhibited ERK phosphorylation, reverted the induced downregulation of Fas and markedly reduced Bcl-XL overexpression in siTRPV2 glioma cells (Figure 3C).

Decreased Fas expression, Akt/protein kinase B phosphorylation, and increased Bcl-XL expression in TRPV2-silenced U87MG cells are ERK dependent

ERK activation has been shown to prevent Fas-mediated apoptosis (6,13) and to regulate cell death at mitochondrial level by modulating Bcl-XL expression (24,29). In addition, increased ERK phosphorylation and reduced sensitivity of cancer cells to chemotherapeutic drug-mediated apoptosis is induced by inhibition of PI3K/Akt pathway (30) that is mainly involved in the control of cell survival (31).

Thus, we evaluated whether the changes in Fas, procaspase 8 and Bcl-XL expression observed in siTRPV2-U87MG transfected cells were dependent on ERK activation. In accordance with mRNA expression (Figure 2C), marked increase of Bcl-XL protein expression, associated with a decrease in Fas and procaspase-8 protein levels, was detected by immunoblot in cell lysates from siTRPV2-U87MG transfected cells (Figure 3C), whereas no changes were found in siGLO-U87MG transfected cells (data not shown). Moreover, PD98059, at the dose that completely inhibited ERK phosphorylation, reverted the induced downregulation of Fas and markedly reduced Bcl-XL overexpression in siTRPV2 glioma cells (Figure 3C).

Neither changes of...
procaspase-8 protein expression nor caspase-8 activation were found in PD98059-treated siTRPV2-U87MG transfected cells (Figure 3C). No significant difference in Bcl-XL, Fas, and procaspase-8 protein expression were found in PD98059-treated versus untreated siGLO-U87MG transfected cells used as control (data not shown).

We also evaluated the role of ERK activation in the control of PI3-kinase pathway in siTRPV2-U87MG transfected cells by evaluating the phosphorylation of the downstream effector molecule Akt/PKB. A basal level of Akt/PKB phosphorylation was observed in siGLO-U87MG transfected cells that was strongly reduced upon TRPV2 silencing. This inhibition was completely reverted by PD98059 treatment (Figure 3D).

Overall, our findings indicate that ERK activation following TRPV2 silencing, alters the balance between proapoptotic and anti-apoptotic signals in that it decreases Fas expression and PI3K/Akt activation and parallelly increases Bcl-XL expression.

**TRPV2 silencing increases survival and proliferation of U87MG glioma cells**

As decreased expression of TRPV2 by small RNA interfering resulted in transcriptional activation of genes controlling cell survival and proliferation, as well as increased ERK phosphorylation, we evaluated the viability and proliferation of siTRPV2- and siTRPV2- and siGLO-U87MG transfected cells by MTT and BrdU incorporation assays, respectively.

Augmented glioma cell viability was evidenced in siTRPV2 cells as compared with siGLO cells (Figure 4A) and was associated with an increased percentage of cells incorporating BrdU (Figure 4B). We further characterized the phenotype of proliferating U87MG cells by analyzing the expression of astrocytic GFAP and neuronal βIII-tubulin markers on BrdU-positive cells. FACS analysis revealed a significant increase in the percentage of proliferating BrdU-βIII-tubulin+ but not in BrdU+GFAP+ siTRPV2 U87MG cells with respect to siGLO control cells (Figure 4C and D).

We also evaluated the role of ERK activation in the control of enhanced siTRPV2-U87MG transfected cells proliferation, using the MEK inhibitor PD98059. A decrease cell viability and percentage of BrdU+ cells was evidenced only in PD98059-treated siTRPV2-U87MG transfected cells compared with untreated cells (Figure 4A and B), being both U87MG GFAP+ and βIII-tubulin+ proliferating cell populations inhibited (Figure 4C and D). Overall, these results suggest ERK activation is a major event controlling the enhanced U87MG cell proliferation upon TRPV2 silencing.

**TRPV2 silencing protects U87MG cells from ERK-dependent apoptosis induced by Fas in combination with chemotherapeutic treatment**

U87MG glioma cells express the death receptor Fas and are moderately sensitive to apoptosis induced by its triggering (32). Thus, we evaluated the effects of specific mAb-mediated Fas triggering in
sTRPV2-U87MG transfected cells. Treatment of siGLO glioma cells with anti-Fas mAb triggered apoptosis, as measured by MTT and Annexin-V assay, whereas sTRPV2-U87MG transfected are completely resistant to anti-Fas mAb-mediated effects (Figure 5A). Then, we evaluated the effects of the combined treatment with anti-Fas mAb (250 ng/ml) and a suboptimal dose of VP-16 (50 μM) or BCNU (100 μM), on apoptotic cell death. We found that Fas triggering in combination with drug treatment did not augment the sensitivity of sTRPV2-U87MG transfected cells to apoptotic cell death, whereas it exerted proapoptotic effects in siGLO-U87MG transfected cells (Figure 5B and C). In addition, according to previously report (33), we suggested that overexpression of Bcl-XL in sTRPV2-U87MG transfected cells conferred less sensitivity of sTRPV2-U87MG transfected cells to both VP-16 and BCNU as compared with siGLO control cells (Supplementary Figure 1 is available at Carcinogenesis Online).

We also evaluated whether inhibition of enhanced ERK activation in sTRPV2-U87MG transfected cells by PD98059 treatment promoted apoptosis and sensitized these cells to Fas-induced cell death. Treatment of sTRPV2-U87MG transfected cells with PD98059 reduced cell viability (4.1 ± 0.3% versus 28.3 ± 2.0%) and induced mitochondrial-dependent apoptosis as shown by the increase in the percentage of Annexin-V+ cells (3.4 ± 0.3% versus 26.3 ± 2.5%) and of cells showing ΔΨm dissipation (8.6 ± 0.4 versus 28.1 ± 0.8%). Moreover, siTRPV2-U87MG transfected cells became more sensitive to apoptosis induced by anti-Fas mAb used alone or in combination with VP-16 or BCNU, following inhibition of ERK activation (Figure 5D, E and F).

Overall, our results indicate that inhibition of ERK activation sensitizes sTRPV2-U87MG transfected cells to mitochondrial-dependent apoptosis induced by Fas in combination with chemotherapeutic treatment.

**TRPV2 transfection reduces survival, increases spontaneous apoptosis and sensitizes MZC glioma cells to Fas- and chemotherapy-induced effects**

To further provide evidences on the role of TRPV2 in survival, proliferation, and sensitivity of glioma cells to Fas and chemotherapy-mediated effects, we transiently transfected MZC glioma cells with TRPV2 cDNA cloned in pCMV vector (pCMV-TRPV2) (Figure 6A and B) and evaluated the effects of TRPV2 transfection by MTT and Annexin-V assays. We found that enforced TRPV2 expression in MZC glioma-transfected cells resulted in a reduced survival and an increased spontaneous and chemotherapy-induced apoptosis as compared with pCMV-MZC-transfected control cells (Figure 6 C, D and E). Moreover, TRPV2 transfection in MZC glioma cells, by inducing Fas overexpression, confers increased sensitivity to Fas-induced apoptosis (Figure 6F).

Overall, these results strengthened the negative role played by TRPV2 in the control of glioma cell survival and proliferation as well as resistance to Fas-induced apoptotic cell death.

**Discussion**

Malignant cell transformation resulting from enhanced proliferation, aberrant differentiation, and resistance to apoptotic cell death is responsible for abnormal tissue growth, which can eventually turn into uncontrolled expansion and invasion, characteristics of cancer. Such transformation is often accompanied by changes in ion channel expression, and consequently by alterations of the cellular responses that they mediate (15).

Human glioma cells express a variety of ion channels (34,35), including TRPV1 channel (16). Herein, we provide evidence on the expression of TRPV2 by glioma cells and tissues and its involvement in ERK-dependent regulation of glioma cell proliferation and susceptibility to Fas-induced apoptosis.

As evaluated by RT–PCR, TRPV2 mRNA and protein were expressed in benign astrocyte tissues; in addition, TRPV2 expression progressively decreased in U87MG and MZC glioma cells and tissues as pathological grade increased, with a marked reduction of TRPV2 in high-grade gliomas.

In conclusion, the loss of TRPV2 mRNA and protein expression in high-grade glioblastomas suggests a negative role for TRPV2 in tumor progression.
In order to explore the molecular mechanisms underlying the functional role of endogenously expressed TRPV2 in the control of glioma cell proliferation and survival, we silenced TRPV2 gene in U87MG cells by RNA interference.

By using a customized PCR array, we found that silencing of TRPV2 gene altered the expression of seven genes regulating glioma cell proliferation and apoptotic cell death. TRPV2 silencing resulted in upregulation of the cyclin E1, cyclin-dependent kinase 2, and E2F1 transcription factor 1 genes controlling G1 to S phase transition, the antiapoptotic Bcl-2 member, Bcl-XL, and of Raf-1 kinase that transduces mitogenic and prosurvival signals (9). In addition, marked downregulation of the proapoptotic death receptor Fas and procaspase-8 genes was also detected in TRPV2 siRNA-transfected U87MG cells.

Modulation of genes promoting cell proliferation and survival by TRPV2 silencing was accompanied by a marked increase in U87MG cell survival and proliferation, as assessed by MTT and BrdU incorporation assays. The increased proliferation was mainly sustained by cells expressing the neuronal βIII-tubulin marker with respect to GFAP+ cells of astrocytic origin. Notably, βIII-tubulin is not only an early neuronal marker but it is also highly expressed in diffuse astrocytic glioma and glioblastomas with an ascending grade of...
Fig. 6. TRPV2 transient transfection in MZC primary glioma cell line. (A) TRPV2 mRNA levels were evaluated by dxRT–PCR in MZC pCMV (empty vector) and MZC pCMV-TRPV2 (TRPV2 encoding vector) transfected cells, 3 days post-transfection. Relative TRPV2 expression, in MZC pCMV-TRPV2 cells, normalized to β-actin mRNA levels, were calculated using MZC pCMV as calibrator. Data shown are the mean ± SD of three separate experiments. Statistical analysis was performed comparing MZC pCMV-TRPV2 with MZC pCMV cells, \( P < 0.01 \). (B) Lysates from MZC-transfected cells were separated on sodium dodecyl sulfate–polyacrylamide gel electrophoresis and probed with specific goat antihuman TRPV2 Ab. glyceraldehydes-3-phosphate dehydrogenase protein levels were evaluated as loading control. Relative TRPV2 expression values were calculated using MZC pCMV as control. Statistical analysis was performed comparing MZC pCMV-TRPV2 with MZC pCMV cells, \( P < 0.01 \). (C) Cell growth of MZC-transfected cells was determined by MTT assay. Data shown are the mean ± SD of three separate experiments. Statistical analysis was performed comparing MZC pCMV-TRPV2 with MZC pCMV cells, \( P < 0.01 \). (D) The percent of Annexin-V+ in MZC pCMV (gray area) and MZC pCMV-TRPV2 (white area) was evaluated by immunofluorescence and fluorescence activated cell sorting (FACS) analysis. (E) VP-16 and BCNU dose response in MZC-transfected cells. Cell viability was determined by MTT assay. Data shown are the mean ± SD of three separate experiments. Statistical analysis was performed comparing MZC pCMV-TRPV2 with MZC pCMV cells, \( P < 0.01 \). (F) (Left panel) Lysates from MZC pCMV and MZC pCMV-TRPV2 transfected cells were separated on sodium dodecyl sulfate–polyacrylamide gel electrophoresis and probed with anti-Fas mAb. Glyceraldehyde-3-phosphate dehydrogenase protein levels were evaluated as loading control, (right panel). The percentage of Annexin-V+ in MZC pCMV and MZC pCMV-TRPV2 transfected cells, treated with anti-Fas mAb (250 ng/ml), was evaluated by immunofluorescence and FACS analysis. Data shown are the mean ± SD of three separate experiments. Statistical analysis was performed comparing MZC pCMV-TRPV2 with MZC pCMV cells, \( P < 0.01 \).
histological malignancy and with correspondingly high proliferative indices (36). In addition, as evaluated by MTT and Annexin-V assays, enforced expression of TRPV2 on low TRPV2-expressing M2C glioma cells resulted in a marked inhibition of cell survival and enhancement of spontaneous apoptosis. Accordingly, myocytes from mTRPV2 transgenic mice undergo spontaneously to massive apoptosis (26).

Glioma cells are moderately sensitive to Fas-induced cell death (32); this sensitivity might be increased by treatment with some antitumor chemotherapeutic agents (37). Our results provide evidence that, in accordance with down-modulation of Fas expression and up-regulation of Bcl-XL, TRPV2 silencing in U87MG cells increased their resistance to apoptotic cell death triggered by anti-Fas-specific mAb used alone or in combination with suboptimal doses of anticancer agents such as VP-16 and BCNU, as shown by the decreased percentage of Annexin-V-positive cells (37).

These findings are in agreement with the increased sensitivity to Fas-induced apoptosis that we evidenced in TRPV2-transfected M2C glioma cells.

ERK activation is a key event controlling survival and proliferation of different cancer cells including glioma (38). ERK activation has been shown to prevent Fas-mediated apoptosis in Jurkat T cells (6–8,13,39); conversely, inhibition of ERK activation increases Fas expression, promotes the apoptosis of Raf-1 overexpressing lymphoma and solid tumor cells (40), and sensitizes HeLa cells to Fas receptor-mediated apoptosis (6). In addition, increased ERK phosphorylation and reduced sensitivity of cancer cells to chemotherapeutic drug-mediated apoptosis is induced by inhibition of PI3K/Akt pathway (31) that is mainly involved in the control of cell survival (32).

We have demonstrated that TRPV2 silencing of U87MG cells is associated with Raf-1 mRNA upregulation and increased ERK phosphorylation; this increase was abrogated by using the specific pharmacological MEK inhibitor PD98059, thus suggesting that impaired TRPV2 expression results in ERK activation. We therefore evaluated the involvement of ERK activation in the survival and proliferation of siTRPV2-U87MG transfected cells and we found that inhibition of ERK activation by PD98059 treatment markedly reduced cell viability and the percentage of BrdU-positive proliferating cells in siTRPV2-U87MG transfected cells. Our findings are consistent with previous results showing that the ERK1/2 activation inhibitor U0126 reduces tumor chemotherapeutic agents (37). Our results provide evidence that, in accordance with down-modulation of Fas expression and up-regulation of Bcl-XL, TRPV2 silencing in U87MG cells increased their resistance to apoptotic cell death triggered by anti-Fas-specific mAb used alone or in combination with suboptimal doses of anticancer agents such as VP-16 and BCNU, as shown by the decreased percentage of Annexin-V-positive cells (37).

In conclusion, we have identified ERK activation as a key signaling event regulating proliferation and chemoresistance in glioma cells exhibiting an impaired expression of TRPV2 channel: ERK activation following TRPV2 silencing drives cell proliferation and prevents glioma cell apoptosis by repressing Fas expression and PI3K/Akt activation and promoting Bcl-XL expression. Further investigations are required to completely understand the relationship between TRPV2 and ERK activation and Fas triggering in glioma cells. Our findings showing that TRPV2 negatively regulates glioma cell survival and proliferation as well as resistance to Fas-induced apoptotic cell death may have important pathophysiological implications, particularly in view of loss of TRPV2 mRNA and protein expression observed during glioma progression. Understanding the role of TRPV2 in the regulation of survival and proliferation signalling pathways could shed light on the mechanisms of resistance of these cancer cells to death receptor- and chemotheraphy-induced apoptosis and lead to novel approaches to primary brain tumor therapy.

**Supplementary material**

Supplementary Figure 1 can be found at http://carcin.oxfordjournals.org/

**Funding**

University of Camerino Grant 2009, AIRC Regional Grant 2007 and AIRC Regional Studentship 2009.

**References**

TRPV2 in proliferation and survival of glioma cells


Received November 19, 2009; revised January 13, 2010; accepted January 16, 2010